BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AEGEA Medical Reports Completion of $13.3 Million Financing


6/30/2011 7:20:46 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- AEGEA Medical Inc., developer of a novel, minimally invasive treatment for abnormal uterine bleeding, reported today that it has completed a $13.3 million private equity financing led by Covidien Ventures. Joining Covidien Ventures in this financing were existing investors Alloy Ventures and Delphi Ventures. The company also announced that Amy Belt, Director of Covidien Ventures, has joined AEGEA’s Board of Directors.

“Capital raised will allow us to complete our product development effort and begin the next stage of clinical testing of our new global endometrial ablation system to treat abnormal uterine bleeding,” commented Don Gurskis, General Manager of AEGEA. “We are pleased with our clinical results to date and look forward to providing a better option.”

Abnormal uterine bleeding impacts one in four women of reproductive age and represents one of the largest and fastest growing commercial opportunities in the women’s health market. Every year, 2.5 million new patients in the United States seek treatment for this disorder.

AEGEA’s system utilizes vapor to rapidly ablate the uterine lining. The ability of the gas to conform to virtually any anatomy is intended to provide complete ablation. This simple minimally invasive procedure can be performed by a gynecologist in an office setting.

"We look forward to proving excellent clinical outcomes and are delighted to formalize our relationship with Covidien," said Doug Kelly, M.D., General Partner of Alloy Ventures.

About AEGEA Medical

AEGEA Medical is a private, clinical-stage medical device company that is developing a novel treatment for abnormal uterine bleeding. The company’s products are not available for sale in the United States. www.aegeamedical.com

About Covidien Ventures

Covidien Ventures is the venture capital investment arm of Covidien plc. Covidien Venture’s investment interests are in markets, products, and technologies that are of long-term interest to Covidien. Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. www.covidienventures.com

About Alloy Ventures

Alloy Ventures is an early-stage IT and Life Sciences venture capital firm with over $1 billion under management. They have helped start and cultivate more than 200 successful companies including such leading companies as Adiana, Barrx, Cambrios, Cameron Health, CoAlign, Crux Biomedical, Forte Bio, Genomatica, Novasys, NuGen, Optimedica, Pacific Biosciences, Raindance, Restoration Robotics, SHN/WebMD, and Verinata. www.alloyventures.com

About Delphi Ventures

Delphi Ventures is a venture capital firm that has focused on early stage investing in medical devices and biotechnology for two decades. With more than $850 million in committed capital, Delphi Ventures has funded over 150 companies. More than 90% of their portfolio companies have either completed an initial public offering or have been acquired by a leading healthcare corporation. www.delphiventures.com

Contact:

AEGEA Medical Inc.Don Gurskis, 650-701-1125 ext. 402General Managerdgurskis@aegeamedical.com



Read at BioSpace.com
Read at Sun Herald
Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES